Genmab A/S Correlations
| GE9 Stock | EUR 261.40 2.00 0.77% |
The current 90-days correlation between Genmab A/S and BioNTech SE is -0.08 (i.e., Good diversification). The correlation of Genmab A/S is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Genmab A/S Correlation With Market
Poor diversification
The correlation between Genmab AS and DJI is 0.63 (i.e., Poor diversification) for selected investment horizon. Overlapping area represents the amount of risk that can be diversified away by holding Genmab AS and DJI in the same portfolio, assuming nothing else is changed.
Genmab |
The ability to find closely correlated positions to Genmab A/S could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Genmab A/S when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Genmab A/S - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Genmab AS to buy it.
Moving together with Genmab Stock
| 0.69 | 4OQ1 | AGNC Investment Corp | PairCorr |
| 0.61 | 943 | FREY EO 250 | PairCorr |
| 0.69 | XSI | Sanyo Chemical Industries | PairCorr |
| 0.79 | SRT3 | Sartorius Aktiengesellscha | PairCorr |
| 0.63 | H3M | Hochschild Mining plc | PairCorr |
| 0.62 | LUS1 | Lang Schwarz Aktieng | PairCorr |
| 0.72 | 5P8 | Blue Foundry Bancorp Earnings Call This Week | PairCorr |
Moving against Genmab Stock
| 0.55 | 14D | tokentus investment | PairCorr |
| 0.5 | JUA | Japan Real Estate | PairCorr |
| 0.4 | 58JA | JAPAN PRIME REALTY Earnings Call This Week | PairCorr |
| 0.34 | 0S2 | UNITED URBAN INV | PairCorr |
| 0.31 | 9NPA | NIPPON PROLOGIS REIT | PairCorr |
| 0.31 | S4C | Nippon Building Earnings Call This Week | PairCorr |
| 0.68 | BDD | CONICO LTD Split | PairCorr |
| 0.65 | DBPD | Xtrackers ShortDAX | PairCorr |
| 0.45 | TTO | TTL Beteiligungs und | PairCorr |
| 0.39 | SOBA | ATT Inc | PairCorr |
Related Correlations Analysis
Please specify at least 3 valid symbols having historical data to build a meaningful correlation cloud. You can use symbol search above to locate your securities.
Be your own money manager
Our tools can tell you how much better you can do entering a position in Genmab A/S without increasing your portfolio risk or giving up the expected return. As an individual investor, you need to find a reliable way to track all your investment portfolios. However, your requirements will often be based on how much of the process you decide to do yourself. In addition to allowing all investors analytical transparency into all their portfolios, our tools can evaluate risk-adjusted returns of your individual positions relative to your overall portfolio.Did you try this?
Run Performance Analysis Now
Performance AnalysisCheck effects of mean-variance optimization against your current asset allocation |
| All Next | Launch Module |
Genmab A/S Corporate Management
Elected by the shareholders, the Genmab A/S's board of directors comprises two types of representatives: Genmab A/S inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Genmab. The board's role is to monitor Genmab A/S's management team and ensure that shareholders' interests are well served. Genmab A/S's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Genmab A/S's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Birgitte MSc | Ex Officer | Profile | |
| Christopher Cozic | Executive Officer | Profile | |
| Tahamtan Ahmadi | Chief VP | Profile | |
| Anthony Mancini | Ex COO | Profile | |
| Judith MD | Executive Officer | Profile |